{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-001073","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.521240+00:00","generated_at":"2026-05-16T11:33:34.577340+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Alumis Phase 3 oral psoriasis drug envudeucitinib meets all endpoints; NDA planned H2 2026","bullets":["Both ONWARD1 and ONWARD2 trials met co-primary endpoints PASI 75 and sPGA 0/1 at Week 16 (p<0.0001).","At Week 24, ~65% achieved PASI 90 and >40% PASI 100, on average across trials.","Safety profile consistent with Phase 2; most common TEAEs were headaches, nasopharyngitis, URIs, and acne.","Envudeucitinib also superior vs apremilast on PASI endpoints at Week 24 (p<0.0001).","Alumis to submit NDA to FDA in H2 2026; topline from SLE Phase 2b expected Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-001073","json":"https://secwatch.observer/filing/0001104659-26-001073.json","markdown":"https://secwatch.observer/filing/0001104659-26-001073.md","text":"https://secwatch.observer/filing/0001104659-26-001073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/0001104659-26-001073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:33:34.577340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}